Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
267 articles with Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.® announced that the Company will participate in the following conferences in March.
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended December 31, 2019 , and provide a general business overview, on Wednesday, February 26, 2020, at 4:30 p.m. ET ( 1:30 p.m
Portola LOSS NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Portola Pharmaceuticals, Inc. Investors of Important March 16th Deadline in Securities Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Portola Pharmaceuticals, Inc. between November 5, 2019 and January 9, 2020, inclusive, of the important March 16, 2020 lead plaintiff deadline in the securities class action.
2/7/2020Pharma and biotech companies strengthen their leadership teams and boards with this weeks appointments.
Wolf Haldenstein Reminds Investors In Portola Pharmaceuticals, Inc. That A Securities Class Action Has Been Filed
Wolf Haldenstein Adler Freeman & Herz LLP, reminds investors that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of the securities of Portola Pharmaceuticals, Inc. between November 5, 2019 and January 9, 2020, inclusive.
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Brings to Portola 20 Years of Clinical Development and Approval Experience
PTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Encourages Investors with Losses to Contact the Firm
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Portola Pharmaceuticals, Inc. from allegations that Portola might have issued misleading information to the investing public..
(PTLA) Alert: Johnson Fistel Launches Investigation into Portola Pharmaceuticals; Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola " or the "Company") for violations of federal securities laws.
Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million
Fourth Quarter Net Revenues of Andexxa Expected to be Approximately $28 Million Including $4 Million in Fourth Quarter Sales from Ondexxya in Europe
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020.
Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke
American Heart Association Quality Improvement Project Promotes Patient Education and Physician Best Practices for Hemorrhagic Stroke
12/16/2019It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL
Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary anticoagulant reversal and replacement guidance statement.
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will be presented at the 2019 American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, in Orlando, Fla.
Andexxa®/Ondexxya® Net Product Revenues of $35.7 million, a 32% Increase Over the Prior Quarter
11/4/2019Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on October 31, 2019
Portola Pharmaceuticals, Inc.® announced that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant to six new employees of inducement stock options to purchase an aggregate of 137,700 shares of common stock, and awards of 66,350 restricted stock units in the aggregate.
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding